论文部分内容阅读
目的观察尤瑞克林(人尿激肽原酶)对急性脑梗死患者的疗效。方法脑梗死患者80例,随机分为治疗组和对照组,每组40例。两组均给予肠溶阿司匹林、阿托伐他汀钙、依达拉奉及营养神经、改善循环等治疗。治疗组在上述基础用药外另用生理盐水250 ml加尤瑞克林0.15 PNA单位,静脉滴注,1次/d,疗程14 d,比较两组疗效并动态观察两组患者治疗前及治疗后14 d、1、3、6个月神经功能缺损评分及改良Rankin量表评分的变化。结果治疗组治疗后的总有效率明显高于对照组,差异有统计学意义(P<0.05);治疗组患者NIHSS评分在治疗后14 d、1、3、6个月均较治疗前降低,且下降程度明显优于对照组,差异有统计学意义(P<0.05)。结论尤瑞克林能够改善急性脑梗死患者的神经功能缺损,临床疗效显著,值得临床广泛应用。
Objective To observe the curative effect of uracil kininogenase on patients with acute cerebral infarction. Methods 80 patients with cerebral infarction were randomly divided into treatment group and control group, 40 cases in each group. Both groups were given enteric-coated aspirin, atorvastatin calcium, edaravone and nutritional nerves, improve circulation and other treatment. The treatment group in addition to the above basic medication with saline 250 ml plus uracil 0.15 PNA unit, intravenous infusion, 1 / d, treatment 14 d, the two groups were compared and the dynamic observation of two groups of patients before and after treatment 14 d, 1,3,6 months neurological deficit score and modified Rankin scale score changes. Results The total effective rate of the treatment group after treatment was significantly higher than that of the control group (P <0.05). The NIHSS score of the treatment group decreased on the 14th day, the 1st, 3rd, and 6th month after treatment, And the degree of decline was significantly better than the control group, the difference was statistically significant (P <0.05). Conclusion Youre Kelin can improve neurological deficits in patients with acute cerebral infarction, clinical efficacy is significant, it is widely used in clinical.